Study of GC101 TIL in Brain Glioma (Soochow2)

This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with malignant glioma . Autologous TILs are expanded from tumor resections and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.

Trial Details

NCT ID
NCT04943913
Phase
EARLY_PHASE1
Sponsor
Shanghai Juncell Therapeutics
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • Tumor Infiltrating Lymphocytes (TIL)
Locations (sample)
  • Suzhou, Jiangsu, China|31.30408,120.59538

Key Eligibility Criteria

  • Age: 18 years to 75 years;
  • Histologically diagnosed as primary/relapsed/metastasized brain glioma;
  • Expected life-span more than 3 months;
  • Karnofsky≥60% or ECOG score 0-2;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →